Gasporox (GPX) investor relations material

Executive summary

• Q3 revenue fell to SEK 3.924m from SEK 9.453m and operating loss was SEK 4.116m; 9M revenue rose to SEK 21.499m and operating loss narrowed to SEK 6.933m.

• Earlier strategic investments are beginning to deliver: the portfolio now includes complete LineArch and LineArch Plus machines, alongside expansion into food packaging inspection and tablet analysis.

• Management entered Q4 with confidence and expects several active projects to reach milestones in 2027.

Financial highlights

• Q3 net sales SEK 3.924m (9.453m); 9M net sales SEK 21.499m (20.281m).

• Q3 operating loss SEK 4.116m, versus SEK 0.060m operating profit; 9M operating loss narrowed to SEK 6.933m from SEK 7.485m.

• Q3 net loss SEK 4.579m (0.305m); 9M net loss SEK 8.330m (8.710m).

• Q3 EBITDA was negative SEK 2.424m versus positive SEK 1.689m; 9M EBITDA was negative SEK 1.871m versus negative SEK 2.715m.

• Q3 cash flow was negative SEK 1.960m; 9M cash flow was positive SEK 0.853m versus SEK 3.677m.

Outlook and guidance

• Management expects a positive Q4 close to 2026 and expressed confidence entering the quarter despite Q3 weakness.

• Several active projects are expected to reach important milestones in 2027; the CE-marked SpectraPore instrument is being prepared for launch in 2026/2027.

• Long-term target: solutions installed on 10–20% of newly installed production lines; goal is positive cash flow without additional capital, subject to market conditions and expansion decisions.